A future generation of evidence-based nutraceuticals that will help to manage health and well-being from the inside out

The gut microbiome is a main contributor to human health and is essentially involved in the development and function of the immune system. Remarkably, gut bacteria are able to induce the development of antibodies against antigens present on their surface. Such antibodies are involved in key function of our immune system.

Humans have natural TFα-antibodies (Thomsen-Friedenreich antibodies), which are induced by gut bacteria carrying the TFα-antigen. These natural TFα-antibodies are important for immune health.

The TFα-antibody level may be affected by modulation of the gut flora, e.g. due to changing habits.

Consequently, a regular dietary supplementation with a bacterium carrying the TFα-antigen can support the natural TFα-antibody level.

CorriX™ provides a solution at highest quality and safety

**Novel pasteurized gut bacterium**
CorriX™ is composed of the heat-treated gut bacterium *Bacteroides xylanisolvens* carrying the TFα-antigen on its surface.

**FDA GRAS and EFSA Novel Food authorized**
CorriX™ is patented, FDA GRAS (Generally Recognized As Safe) and EFSA authorized as Novel Food. Safe for daily human consumption.

CorriX™ is developed as a natural food, beverage and supplement ingredient.

**Unique effect**
CorriX™ is the first evidence-based nutraceutical to support the physiologic development of specific natural TFα-antibodies involved in our immune health.

**Highest scientific standards**
Developed in by now 10 years from lab to market, CorriX™ is backed with scientific research published in international peer-reviewed journals including a double-blind, randomized, placebo-controlled human study.

CorriX™ applications
- Food, beverage and supplement ingredient
- Pasteurized without losing efficacy (easy handling, transport and storage as well as maximum safety)
- For everyday use year round, safe and effective for daily consumption
- Marketing dosages (given in cells per day) analyzed in a human trial
- Kosher
Research

Human efficacy study
A randomized, double-blind, placebo controlled trial demonstrated that CorriX™ induces the development of natural TFα-IgM antibodies in humans [2]

Animal efficacy study
TFα-antigen-expressing Bacteroides induced the development of natural TFα-antibodies in mice [1]

Safety
The CorriX™-strain Bacteroides xylanisolvens is safe for human consumption [3-5]

Discovery
The CorriX™-strain Bacteroides xylanisolvens was isolated from a healthy human gut and is a new Bacteroides xylanisolvens strain.[4]

Human efficacy study: CorriX™ increases the TFα-antibody level in humans [2]

A double-blind, placebo-controlled study involving 140 healthy volunteers revealed that the oral uptake of pasteurized Bacteroides xylanisolvens (CorriX™) was able to increase the level of TFα-specific IgM antibodies:

Up to 50% and 75% of volunteers presented a significant increase in the TFα-specific IgM antibody level after 3 and 6 weeks of intake, respectively. The effect was dose-dependent, physiological and reverted after stopping the intake.

Reference List

Contact us: Avitop GmbH
Robert-Rößle-Str. 10
13125 Berlin, Germany
info@avitop.de
phone: +49 (0) 30 9489 2660
www.avitop-health.com

This document contains science, research, and technical documents meant only for product manufacturers and related professionals.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This statement has not been reviewed by food authorities (FDA, EFSA).